PIK3CA and hepatocellular carcinoma: NF1 mutations have been reported in 10% of HCC samples and such tumors may thus be sensitive to PI3K/AKT/mTOR and MAPK inhibitors.[7, 24] BAP1 rearrangement results in a truncation of the BAP1 protein (Figure 2).